Cellid Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

1.40

EPS

—

Div Yield, %

—

Shrs. gr., 5y

25.07%

Rev. gr., 5y

Revenues

8.84b

+112.28%

Net income

-12.07b

L-1.55%

CFO

-10.22b

L-0.94%

Dividend

Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Cellid, a South Korean firm established in 2006, specializes in creating immunotherapeutic vaccines designed to combat various cancers and infectious ailments. Their pipeline includes BVAC-C, which targets cervical, head and neck, anal, and genital cancers linked to the human papillomavirus (HPV) antigen. They are also advancing BVAC-B for gastric, ovarian, lung, and pancreatic cancers, focusing on the HER-2/neu antigen, and BVAC-P, intended for prostate, urinary tract, and brain cancers by leveraging PAP/PSMA antigens. Furthermore, Cellid is working on BVAC-M for melanoma and other cancers, utilizing GP100/MAGE-A3 antigens, alongside BVAC-Neo, a personalized immunotherapeutic vaccine solution.

URL

http://www.cellid.co.kr/

IPO date

Feb 20, 2019

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT